Pernix Therapeutics Holdings Inc

Entity type image
Type: Company
Name: Pernix Therapeutics Holdings Inc
First reported May 17 2013 - Updated May 17 2013 - 1 reports

Pernix Therapeutics Holdings Price Target Cut to $3.00 (PTX)

Pernix Therapeutics Holdings (NYSE: PTX) had its price target lowered by Cantor Fitzgerald from $7.00 to $3.00 in a research report sent to investors on Wednesday morning, ARN reports. The firm currently has a hold rating on the stock.“The company may ... [Published Mideast Time - May 17 2013]
First reported May 16 2013 - Updated May 16 2013 - 1 reports

Pernix Therapeutics quietly reveals new CEO

In its quarterly earnings report, the Woodlands-based Pernix Therapeutics Holdings Inc. (Nasdaq: PTX) informed investors it was getting a new CEO.The former CEO, Cooper Collins, will remain a member of the board of directors and serve as chief strategic ... [Published Houston Business Journal - May 16 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports
Stifel Nicolaus
Stifel Nicolaus

Pernix Therapeutics Holdings Price Target Lowered to $4.00 at Stifel Nicolaus (PTX)

Pernix Therapeutics Holdings (NYSE: PTX) had its price target lowered by Stifel Nicolaus from $10.00 to $4.00 in a research report sent to investors on Monday morning, Analyst Ratings Network reports. The firm currently has a buy rating on the stock.Pernix ... [Published Mideast Time - May 15 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports
Cantor Fitzgerald LP
Cantor Fitzgerald LP

UPDATE: Cantor Fitzgerald Lowers PT on Pernix Therapeutics after Mike Pearce Named CEO

In a report published Wednesday morning, Cantor Fitzgerald analyst Irina Rivkind reiterated a Hold rating on Pernix Therapeutics (NASDAQ: PTX) and lowered the price target from $7 to $3.In the report, Cantor Fitzgerald wrote, "The company may take at ... [Published Benzinga.com - May 15 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports
New York Stock Exchange
New York Stock Exchange

Pernix Therapeutics Holdings Price Target Cut to $3.00 (PTX)

Equities research analysts at Cantor Fitzgerald decreased their price target on shares of Pernix Therapeutics Holdings (NYSE: PTX)Other equities research analysts have also recently issued reports about the stock. Analysts at Needham & Company cut their ... [Published American Banking News - Stock Ratings - May 15 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports

Pernix Therapeutics Reports 1Q 2013 Financial Results

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, announced financial results for the quarter ended March 31. In a release dated May 10, the Company said that for the first quarter of 2013, net revenues increased by approximately ... [Published Individual.com - May 15 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports

Pernix Therapeutics Holdings Price Target Lowered to $6.00 at Needham & Company (PTX)

Needham & Company lowered their price target on shares of Pernix Therapeutics Holdings (NYSE: PTX)PTX has been the subject of a number of other recent research reports. Analysts at Stifel Nicolaus cut their price target on shares of Pernix Therapeutics ... [Published American Banking News - May 15 2013]
First reported May 13 2013 - Updated May 13 2013 - 1 reports

Form 4 PERNIX THERAPEUTICS HOLD For: May 10 Filed by: Pearce Michael Cooper

StreetInsider.com - Form 4 PERNIX THERAPEUTICS HOLD For: May 10 Filed by: Pearce Michael Cooper ... [Published Street Insider - May 13 2013]
First reported May 13 2013 - Updated May 13 2013 - 1 reports

Form 8-K PERNIX THERAPEUTICS HOLD For: May 08

StreetInsider.com - Form 8-K PERNIX THERAPEUTICS HOLD For: May ... [Published Street Insider - May 13 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Pernix Therapeutics, Inc. Reports First Quarter 2013 Financial Results

Pernix Therapeutics Holdings, Inc. (âPernixâ or the âCompanyâ) (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2013. Financial Results For the first quarter of 2013, net revenues increased ... [Published BioSpace - May 10 2013]
First reported May 10 2013 - Updated May 10 2013 - 1 reports

Pernix Therapeutics Holdings (PTX) Posts Quarterly Earnings, Misses Expectations By $0.07 EPS

Pernix Therapeutics Holdings (NYSE: PTX) posted its quarterly earnings results on Friday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.07, ARN reports.Several analysts have also recently ... [Published American Banking News - Earnings - May 10 2013]
First reported May 03 2013 - Updated May 03 2013 - 2 reports

Pernix Therapeutics to Report First Quarter 2013 Financial Results on May 10, 2013

THE WOODLANDS, Texas - (BUSINESS WIRE) - Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its first quarter 2013 financial results before the U.S. stock market opens on Friday, ... [Published NewsBlaze - May 03 2013]

Quotes

In the report, Cantor Fitzgerald wrote, "The company may take at least a year to stabilize, in our view: The new CEO indicated that the focus for right now is on integration, cutting excess costs, and on cash generation from monetizing non-core assets. Furthermore, the company plans to look for additional deal opportunities that may be structured as partnerships and would not use up cash Management believes that revenues will ramp back up in 2H:13 but this is predicated on commercial execution (and a strong cold/cough season, in our view). We model some improvement to gross margins over time but note that Pernix is inherently less profitable than other branded specialty pharma companies. The company plans to launch Dr. Cocoa in the 2013 2014 cold season, and management indicated that it has contracts from major retail pharmacy chains, which is somewhat encouraging."
UPDATE: Cantor Fitzgerald Lowers PT on Pernix Therapeutics after Mike Pearce Named CEO [Published Benzinga.com - May 15 2013]
...3 million, or $0.13 per basic and diluted share. Cooper Collins, President and Chief Executive Officer of Pernix, said, "In the first quarter of 2013, we completed the acquisition of Somaxon, and in May 2013, our sales force will be re-launching Silenor which is a non-seasonal product for insomnia that broadens our product line. We have restructured and refocused our sales force, and we continue to integrate Cypress and Hawthorn, are on track to launch Dr. Cocoa, an OTC chocolate cough and cold product for the 2013-14 cough and cold season, and plan to initiate our phase III clinical trial for our pediatric product in the summer of 2013."
Pernix Therapeutics Reports 1Q 2013 Financial Results [Published Individual.com - May 15 2013]
...ollaboration with the company to include another aspect of our technology platform," said Lawson Macartney, Ph D , chief executive officer of Ambrx. "We look forward to working together to further utilize Ambrx's technology to discover and advance these antibody drug conjugates for oncology indications."
Ambrx and Bristol-Myers Squibb Collaborate on Discovery; Bristol-Myers Squibb Receives US FDA sND ... [Published BioMedReports - May 04 2013]
...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."
PTX, ONCY, GGB, CMLP, BBEP, GMO Expected To Be Down Before Next Earnings Releases [Published Individual.com - Apr 23 2013]

More Content

All (71) | News (38) | Reports (1) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (29)
sort by: Date | Relevance
Pernix Therapeutics Holdings Price Target Cut t... [Published Mideast Time - May 17 2013]
Pernix Therapeutics quietly reveals new CEO [Published Houston Business Journal - May 16 2013]
Pernix Therapeutics Holdings Price Target Lower... [Published Mideast Time - May 15 2013]
UPDATE: Cantor Fitzgerald Lowers PT on Pernix T... [Published Benzinga.com - May 15 2013]
Investment Analysts’ Price Target Changes for M... [Published American Banking News - May 15 2013]
Pernix Therapeutics Holdings Price Target Cut t... [Published American Banking News - Stock Ratings - May 15 2013]
Pernix Therapeutics Reports 1Q 2013 Financial R... [Published Individual.com - May 15 2013]
Pernix Therapeutics Holdings Price Target Lower... [Published American Banking News - May 15 2013]
Pernix Reports Loss in 1Q Zacks [Published Yahoo! Finance - May 13 2013]
Form 4 PERNIX THERAPEUTICS HOLD For: May 10 Fil... [Published Street Insider - May 13 2013]
Form 8-K PERNIX THERAPEUTICS HOLD For: May 08 [Published Street Insider - May 13 2013]
Pernix Therapeutics Holdings Management Discuss... [Published Seeking Alpha - May 10 2013]
Pernix Therapeutics, Inc. Reports First Quarter... [Published BioSpace - May 10 2013]
Pernix Therapeutics Holdings (PTX) Posts Quarte... [Published American Banking News - Earnings - May 10 2013]
Pernix Therapeutics Holdings Inc Issues FY 2013... [Published Reuters UK - May 10 2013]
Pernix Therapeutics Reports First Quarter 2013 ... [Published Business Wire Health News - May 10 2013]
Earnings Scheduled For May 10, 2013 [Published Benzinga.com - May 10 2013]
Pernix Therapeutics to Report First Quarter 201... [Published The Paper Magazine - May 04 2013]
Ambrx and Bristol-Myers Squibb Collaborate on D... [Published BioMedReports - May 04 2013]
Pernix Therapeutics to Report First Quarter 201... [Published NewsBlaze - May 03 2013]
Pernix Therapeutics to Report First Quarter 201... [Published Street Insider - May 03 2013]
Pernix Therapeutics to Report First Quarter 201... [Published Business Wire Manufacturing News - May 03 2013]
Pernix Therapeutics to Report First Quarter 201... [Published Business Wire Health News - May 03 2013]
SciClone Pharmaceuticals, Inc. (SCLN): Insiders... [Published InsiderMonkey.com - May 03 2013]
DEF 14A - PERNIX THERAPEUTICS HOLDINGS, INC. (0... [Published SEC - Apr 26 2013]
Form 8-K PERNIX THERAPEUTICS HOLD For: Apr 19 [Published Street Insider - Apr 25 2013]
Pernix Therapeutics to Present at the 12th Annu... [Published Business Wire - Apr 23 2013]
Pernix Therapeutics to Present at the 12th Annu... [Published Business Wire Health News - Apr 23 2013]
PTX, ONCY, GGB, CMLP, BBEP, GMO Expected To Be ... [Published Individual.com - Apr 23 2013]
Stock Analysts’ Downgrades for April, 22nd (ABM... [Published American Banking News - Apr 22 2013]
1 2 3
In Focus
  •  
Cooper Collins, Michael Pearce, Michael Cooper, [more]
  •  
Somaxon Pharmaceuticals Inc, Hawthorn Pharmaceuticals Inc, New York Stock Exchange, [more]
  •  
FDA Food & Drug Administration, NIST National Institute of Standards & Technology, US Securities and Exchange Commission, [more]
  •  
8-k, Acquisition, Healthcare Conference, [more]
  •  
silenor, Cedax, REOLYSIN, [more]
  •  
The Woodlands (United States), Dallas (Texas, United States), San Diego (California, United States), [more]
  •  
United States, Switzerland, Brazil, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
IT, Banking & Financial Services, Health, [more]
Business Wire Health News, SEC Filings, EON Health & Medicine, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Pike Electric Gets a Thumbs Down and 3 More Ana... [Published Wall St. Cheat Sheet - Mar 19 2013]
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...
Dycom Will Outperform and 4 More Analyst Notes ... [Published Wall St. Cheat Sheet - Mar 19 2013]
Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up ...
Molycorp Files 10K Extension & 3 Stocks Hitting... [Published Wall St. Cheat Sheet - Mar 01 2013]
Molycorp  ( NYSE:MCP ): Closing price $6.14 The firm needs an extension of time to file its annual report on Form 10-K, without which it would have to be filed no later than March 1. The  filing delay is necessary so that it can determine the amount ...
1

Press Releases

sort by: Date | Relevance
Pernix Therapeutics Reports First Quarter 2013 ... [Published Business Wire Health News - May 10 2013]
Pernix Therapeutics to Report First Quarter 201... [Published Business Wire Manufacturing News - May 03 2013]
Pernix Therapeutics to Report First Quarter 201... [Published Business Wire Health News - May 03 2013]
Pernix Therapeutics to Present at the 12th Annu... [Published Business Wire - Apr 23 2013]
Pernix Therapeutics to Present at the 12th Annu... [Published Business Wire Health News - Apr 23 2013]
1 2 3 4 5 6
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.